Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT06931717 2026-04-14

ARCH

Phase 3 Recruiting

390 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

162 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06171750 2026-03-06

ANCHOR

Phase 1 Recruiting

97 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Skin Neoplasms

NCT06918132 2026-02-24

N-PLANC

Phase 2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06219317 2026-02-23

ICARS

Phase 2 Recruiting

136 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06465329 2026-02-12

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Phase 2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06656598 2026-02-11

SPORADIC

Phase 2 Recruiting

152 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

300 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06917573 2025-11-19

PALACE

Phase 2 Recruiting

63 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06088771 2025-05-08

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Phase 1/2 Recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06090266 2025-01-07

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Phase 1/2 Recruiting

168 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

Clinical Trials

CEMI-LUNG

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

LIMITLESS

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

LuCa-MERIT-1

ARCH

IMMUNOLIFE2

ANCHOR

N-PLANC

ICARS

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

SPORADIC

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

PALACE

VIRO-25

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

EROS